Ganoderma lucidum inhibits proliferation of human ovarian cancer cells by suppressing VEGF expression and up-regulating the expression of connexin 43.
Bottom Line:
Ganoderma lucidum (G. lucidum, Reishimax) is an herbal mushroom known to have inhibitory effect on tumor cell growth.G. lucidum treatment resulted in reduced proliferation of HOCC.Furthermore, knockdown of Cx43 expression in HOCC abrogated the effect of G. lucidum on cell proliferation without alteration of G. lucidum-induced attenuation of VEGF expression.
View Article:
PubMed Central - PubMed
Affiliation: Department of Obstetrics and Gynecology, The Affiliated Shengjing Hospital, China Medical University, 36 Sanhao Street, Heping district, Shenyang 110004, People's Republic of China. daishy2014@163.com.
ABSTRACT
Show MeSH
Background: Ganoderma lucidum (G. lucidum, Reishimax) is an herbal mushroom known to have inhibitory effect on tumor cell growth. However, the molecular mechanisms responsible for its anti-proliferative effects on the ovarian cancer have not been fully elucidated. Methods: Human ovarian cancer cells HO 8910 (HOCC) and human primary ovarian cells (HPOC) were treated with G. lucidum. Effects of G. lucidum treatment on cell proliferation were studied by MTT assay. The expression of vascular endothelial growth factor (VEGF) and connexin 43 (Cx43) were measured by immunohistochemistry and real time polymerase chain reaction. To study the molecular mechanism of CX43 mediated anti-tumor activity, small interference RNA (siRNA) was used to knockdown Cx43 expression in HOCC. Results: G. lucidum treatment resulted in reduced proliferation of HOCC. Inhibition of proliferation was accompanied by a decrease in VEGF expression and increase in Cx43 expression in the cancer cells. The extent of immune-reactivity of Cx43 or VEGF in cancer cells were correlated with the concentrations of G. lucidum used for treatment. Furthermore, knockdown of Cx43 expression in HOCC abrogated the effect of G. lucidum on cell proliferation without alteration of G. lucidum-induced attenuation of VEGF expression. Conclusions: G. lucidum inhibits ovarian cancer by down-regulating the expression of VEGF and up-regulating the downstream Cx43 expression. G. lucidum may be a promising therapeutic agent for the treatment of ovarian cancer. Related in: MedlinePlus |
![]() Related In:
Results -
Collection
License 1 - License 2 getmorefigures.php?uid=PMC4232730&req=5
Fig1: Growth curve of HOCC and HPOC in DMEM with 5% BCS or with addition of 10 ug/ml G. lucidum. Proliferation ratio (%) indicates the cell proliferation rate at other times compared with that at 0 h when cell numbers are considered as 100%. n = 5, Data are shown as mean ± S.D. *P < 0.05 vs HOCC + G. lucidum. Mentions: The HOCC and HPOC were cultured in DMEM with 1 5% FBS for 24, 48 and 72 h. The results for cell proliferation are shown in Figure 1. G. lucidum inhibited the growth of HPOC by less than 10% while it inhibited the growth of HOCC by up to 60% after 3 days of culture. These results suggest that G. lucidum effectively prevents the cell proliferation in HOCC.Figure 1 |
View Article: PubMed Central - PubMed
Affiliation: Department of Obstetrics and Gynecology, The Affiliated Shengjing Hospital, China Medical University, 36 Sanhao Street, Heping district, Shenyang 110004, People's Republic of China. daishy2014@163.com.
Background: Ganoderma lucidum (G. lucidum, Reishimax) is an herbal mushroom known to have inhibitory effect on tumor cell growth. However, the molecular mechanisms responsible for its anti-proliferative effects on the ovarian cancer have not been fully elucidated.
Methods: Human ovarian cancer cells HO 8910 (HOCC) and human primary ovarian cells (HPOC) were treated with G. lucidum. Effects of G. lucidum treatment on cell proliferation were studied by MTT assay. The expression of vascular endothelial growth factor (VEGF) and connexin 43 (Cx43) were measured by immunohistochemistry and real time polymerase chain reaction. To study the molecular mechanism of CX43 mediated anti-tumor activity, small interference RNA (siRNA) was used to knockdown Cx43 expression in HOCC.
Results: G. lucidum treatment resulted in reduced proliferation of HOCC. Inhibition of proliferation was accompanied by a decrease in VEGF expression and increase in Cx43 expression in the cancer cells. The extent of immune-reactivity of Cx43 or VEGF in cancer cells were correlated with the concentrations of G. lucidum used for treatment. Furthermore, knockdown of Cx43 expression in HOCC abrogated the effect of G. lucidum on cell proliferation without alteration of G. lucidum-induced attenuation of VEGF expression.
Conclusions: G. lucidum inhibits ovarian cancer by down-regulating the expression of VEGF and up-regulating the downstream Cx43 expression. G. lucidum may be a promising therapeutic agent for the treatment of ovarian cancer.